ATE431342T1 - Inhibitoren von fettsäureamidhydrolase - Google Patents
Inhibitoren von fettsäureamidhydrolaseInfo
- Publication number
- ATE431342T1 ATE431342T1 AT03759771T AT03759771T ATE431342T1 AT E431342 T1 ATE431342 T1 AT E431342T1 AT 03759771 T AT03759771 T AT 03759771T AT 03759771 T AT03759771 T AT 03759771T AT E431342 T1 ATE431342 T1 AT E431342T1
- Authority
- AT
- Austria
- Prior art keywords
- fatty acid
- acid amide
- faah
- inhibitors
- amide hydrolase
- Prior art date
Links
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 title abstract 5
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 230000002860 competitive effect Effects 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 150000004866 oxadiazoles Chemical class 0.000 abstract 1
- 150000002916 oxazoles Chemical class 0.000 abstract 1
- 150000004867 thiadiazoles Chemical class 0.000 abstract 1
- 150000003557 thiazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41724702P | 2002-10-08 | 2002-10-08 | |
| PCT/US2003/031975 WO2004033652A2 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE431342T1 true ATE431342T1 (de) | 2009-05-15 |
Family
ID=32093990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03759771T ATE431342T1 (de) | 2002-10-08 | 2003-10-08 | Inhibitoren von fettsäureamidhydrolase |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7662971B2 (de) |
| EP (2) | EP2093220A3 (de) |
| JP (1) | JP4628789B2 (de) |
| KR (1) | KR20050070041A (de) |
| CN (1) | CN1703407A (de) |
| AT (1) | ATE431342T1 (de) |
| AU (1) | AU2003275493A1 (de) |
| BR (1) | BR0314980A (de) |
| CA (1) | CA2501575A1 (de) |
| DE (1) | DE60327640D1 (de) |
| EA (1) | EA008767B1 (de) |
| ES (1) | ES2325686T3 (de) |
| MX (1) | MXPA05003762A (de) |
| WO (1) | WO2004033652A2 (de) |
| ZA (1) | ZA200501837B (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6462054B1 (en) | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| BR0314980A (pt) | 2002-10-08 | 2005-08-09 | Scripps Research Inst | Inibidores de hidrolase de amida de ácido graxo |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| DE102004039326A1 (de) * | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Neue medizinische Verwendungen und Verfahren |
| US7351724B2 (en) | 2004-10-15 | 2008-04-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| AR055831A1 (es) | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| PE20070099A1 (es) | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
| EP1954137A4 (de) | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-keto-oxazole als modulatoren der fettsäureamidhydrolase |
| JP2009527483A (ja) | 2006-02-17 | 2009-07-30 | ザ・スクリプス・リサーチ・インステイチユート | 脂肪酸アミドヒドロラーゼの調節因子としてのオキサゾールケトン |
| WO2008013963A2 (en) | 2006-07-28 | 2008-01-31 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| WO2008030532A2 (en) * | 2006-09-08 | 2008-03-13 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
| AU2008257154B2 (en) * | 2007-05-25 | 2014-03-06 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| EP2161997A4 (de) * | 2007-05-31 | 2011-04-06 | Scripps Research Inst | Tricyclische inhibitoren von fettsäureamidhydrolase |
| CA2714743C (en) * | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| US20110184026A1 (en) * | 2008-06-19 | 2011-07-28 | Boger Dale L | C4-substituted alpha-keto oxazoles |
| WO2010005572A2 (en) * | 2008-07-09 | 2010-01-14 | The Scripps Research Institute | Alpha-keto heterocycles as faah inhibitors |
| EP2321288B1 (de) | 2008-08-04 | 2014-03-19 | Merck Sharp & Dohme Corp. | Als inhibitoren von faah geeignete oxazolderivate |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8598356B2 (en) | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| JP5657566B2 (ja) * | 2008-12-24 | 2015-01-21 | バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． | 医薬品 |
| AR076687A1 (es) * | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| ES2626246T3 (es) | 2009-09-09 | 2017-07-24 | Sumitomo Dainippon Pharma Co., Ltd. | Derivado de 8-oxodihidropurina |
| CA2782797C (en) | 2009-10-02 | 2018-08-07 | Avexxin As | Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles |
| US20120225097A1 (en) | 2009-11-12 | 2012-09-06 | Hawryluk Natalie A | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| BR112012018913A2 (pt) * | 2010-01-28 | 2017-06-20 | Merck Sharp & Dohme | "composição farmacêutica, e, uso da composição" |
| PT2544679T (pt) | 2010-03-12 | 2019-07-11 | Omeros Corp | Inibidores de pde-10 e composições e métodos relacionados |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| US9006433B2 (en) | 2010-04-21 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| ES2888231T3 (es) * | 2010-09-20 | 2022-01-03 | Sirna Therapeutics Inc | Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos |
| CN102964311B (zh) * | 2011-09-01 | 2016-03-09 | 大丰海嘉诺药业有限公司 | 一种合成4-甲基-5-烷氧基噁唑的方法 |
| ES2648188T3 (es) * | 2012-02-17 | 2017-12-29 | Epitech Group S.P.A. | Composiciones y métodos para la modulación de amidasas específicas para N-aciletanolaminas para ser usadas en la terapia de enfermedades inflamatorias |
| CN105102438B (zh) | 2013-01-29 | 2019-04-30 | 埃维克辛公司 | 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物 |
| WO2015066277A1 (en) | 2013-11-01 | 2015-05-07 | Merial Limited | Antiparisitic and pesticidal isoxazoline compounds |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| US20160244860A1 (en) * | 2015-02-20 | 2016-08-25 | Cytec Industries Inc. | Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions |
| US9879002B2 (en) | 2015-04-24 | 2018-01-30 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| EP3095787A1 (de) * | 2015-05-22 | 2016-11-23 | Universiteit Leiden | Pharmazeutisch aktive zusammensetzungen als dag-lipaseinhibitoren |
| US9920045B2 (en) | 2015-11-04 | 2018-03-20 | Omeros Corporation | Solid state forms of a PDE10 inhibitor |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| JP7531351B2 (ja) | 2019-11-13 | 2024-08-09 | 東京エレクトロン株式会社 | 基板処理方法、基板処理装置、および基板処理システム |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA19269A1 (fr) * | 1980-09-16 | 1982-04-01 | Lilly Co Eli | Perfectionnement relatif a des derives de n-arylbenzamides . |
| US5646289A (en) * | 1994-10-24 | 1997-07-08 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
| US6462054B1 (en) | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| US20020103192A1 (en) | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| BR0314980A (pt) | 2002-10-08 | 2005-08-09 | Scripps Research Inst | Inibidores de hidrolase de amida de ácido graxo |
-
2003
- 2003-10-08 BR BR0314980-3A patent/BR0314980A/pt not_active IP Right Cessation
- 2003-10-08 ES ES03759771T patent/ES2325686T3/es not_active Expired - Lifetime
- 2003-10-08 EP EP09006391A patent/EP2093220A3/de not_active Withdrawn
- 2003-10-08 EA EA200500633A patent/EA008767B1/ru unknown
- 2003-10-08 DE DE60327640T patent/DE60327640D1/de not_active Expired - Lifetime
- 2003-10-08 WO PCT/US2003/031975 patent/WO2004033652A2/en not_active Ceased
- 2003-10-08 CA CA002501575A patent/CA2501575A1/en not_active Abandoned
- 2003-10-08 JP JP2004543576A patent/JP4628789B2/ja not_active Expired - Fee Related
- 2003-10-08 KR KR1020057006019A patent/KR20050070041A/ko not_active Withdrawn
- 2003-10-08 EP EP03759771A patent/EP1549624B1/de not_active Expired - Lifetime
- 2003-10-08 CN CNA2003801009944A patent/CN1703407A/zh active Pending
- 2003-10-08 US US10/528,552 patent/US7662971B2/en not_active Expired - Fee Related
- 2003-10-08 AT AT03759771T patent/ATE431342T1/de not_active IP Right Cessation
- 2003-10-08 AU AU2003275493A patent/AU2003275493A1/en not_active Abandoned
- 2003-10-08 MX MXPA05003762A patent/MXPA05003762A/es not_active Application Discontinuation
-
2005
- 2005-03-03 ZA ZA200501837A patent/ZA200501837B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060111359A1 (en) | 2006-05-25 |
| ES2325686T3 (es) | 2009-09-14 |
| AU2003275493A1 (en) | 2004-05-04 |
| BR0314980A (pt) | 2005-08-09 |
| MXPA05003762A (es) | 2005-07-22 |
| EA200500633A1 (ru) | 2005-10-27 |
| EP2093220A3 (de) | 2009-11-11 |
| ZA200501837B (en) | 2006-06-28 |
| DE60327640D1 (de) | 2009-06-25 |
| WO2004033652A2 (en) | 2004-04-22 |
| CA2501575A1 (en) | 2004-04-22 |
| WO2004033652A3 (en) | 2004-09-16 |
| EA008767B1 (ru) | 2007-08-31 |
| EP2093220A2 (de) | 2009-08-26 |
| JP2006502229A (ja) | 2006-01-19 |
| US7662971B2 (en) | 2010-02-16 |
| KR20050070041A (ko) | 2005-07-05 |
| EP1549624A4 (de) | 2006-09-20 |
| CN1703407A (zh) | 2005-11-30 |
| JP4628789B2 (ja) | 2011-02-09 |
| EP1549624A2 (de) | 2005-07-06 |
| EP1549624B1 (de) | 2009-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE431342T1 (de) | Inhibitoren von fettsäureamidhydrolase | |
| CO5251452A1 (es) | Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar | |
| EA200600509A1 (ru) | Соединения пиримидотиофена | |
| NO20064418L (no) | Nye amido-substituerte hydroksy-6-fenylfenantridiner | |
| WO2004018465A3 (en) | Benzonaphthyridines with pde 3/4 inhibiting activity | |
| ATE435219T1 (de) | Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase | |
| MA29029B1 (fr) | Composes de thiadiazole et leurs procedes d'utilisation | |
| LU92555I2 (fr) | Empagliflozine et ses sels, en particulier Empagliflozine (*) (*) l'ingrédient actif approuvé est l'Empagliflozine de formule (1S)-1,5anhydro-1-C-{4-chloro-3-¬(4-{¬(3S)-oxolan-3-yloxyl}phényl)méthylphényl}-D-glucitol | |
| EP1601357A4 (de) | Heterocyclische kinase-hemmer: verfahren zur verwendung und synthese | |
| ATE368034T1 (de) | Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase | |
| CY1110498T1 (el) | Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα | |
| ATE348816T1 (de) | 2,5-dioxoimidazolidin-4-ylacetamide und analoga als inhibitoren von metalloproteinase mmp12 | |
| IS7337A (is) | Nikótínamíð afleiður nytsamlegar sem P38 hindrar | |
| EP1507541A4 (de) | Hemmer und anwendungsverfahren dafür | |
| ATE365551T1 (de) | Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis | |
| ATE304003T1 (de) | Thiadiazole und oxadiazole sowie ihre verwendung als phosphodiesterase-7 inhibitoren | |
| NO20040819L (no) | Piezoelektrisk biologisk lydmonitor med kretskort. | |
| DE60335731D1 (de) | Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer | |
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| DE60313289D1 (de) | Kontrollierte synthese von ziprasidon | |
| EP1616866A4 (de) | M-stage-kinesin-inhibitor | |
| DE602004011255D1 (de) | Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| NZ536103A (en) | Peptide deformylase inhibitors | |
| EP1636182A4 (de) | Prodrugs von inhibitoren vom mitotischem kinesin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |